| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MTCH2 |
| Uniprot No | Q9Y6C9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-303aa |
| 氨基酸序列 | MADAASQVLLGSGLTILSQPLMYVKVLIQVGYEPLPPTIGRNIFGRQVCQLPGLFSYAQHIASIDGRRGLFTGLTPRLCSGVLGTVVHGKVLQHYQESDKGEELGPGNVQKEVSSSFDHVIKETTREMIARSAATLITHPFHVITLRSMVQFIGRESKYCGLCDSIITIYREEGILGFFAGLVPRLLGDILSLWLCNSLAYLVNTYALDSGVSTMNEMKSYSQAVTGFFASMLTYPFVLVSNLMAVNNCGLAGGCPPYSPIYTSWIDCWCMLQKEGNMSRGNSLFFRKVPFGKTYCCDLKMLI |
| 预测分子量 | 33,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MTCH2重组蛋白的3篇参考文献(基于公开信息模拟整理，非真实文献)：
---
1. **文献名称**: "Recombinant MTCH2 Expression in E. coli: Purification and Functional Characterization"
**作者**: Smith J. et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了重组MTCH2蛋白，通过体外实验验证其与线粒体膜结合的能力，并发现其参与调节细胞凋亡的关键结构域。
2. **文献名称**: "Structural Insights into MTCH2-Mediated Mitochondrial Apoptosis"
**作者**: Lee S. et al.
**摘要**: 利用重组MTCH2蛋白进行X射线晶体学研究，揭示了其与BAX蛋白相互作用的分子机制，为MTCH2在凋亡信号通路中的调控作用提供了结构基础。
3. **文献名称**: "MTCH2 Recombinant Protein Modulates Lipid Metabolism in Adipocytes"
**作者**: Zhang Y. et al.
**摘要**: 通过体外表达MTCH2重组蛋白，证明其通过影响线粒体膜脂质转运，调控脂肪细胞代谢平衡，提示MTCH2在肥胖相关疾病中的潜在治疗靶点。
---
如需具体文献，建议在PubMed或Google Scholar中搜索关键词 "MTCH2 recombinant protein" "mitochondrial carrier homolog 2 expression" 等获取最新研究。
**Background of MTCH2 Recombinant Protein**
MTCH2 (Mitochondrial Carrier Homolog 2), also known as mitochondrial carrier protein HTRA2/OMI, is a nuclear-encoded protein localized to the mitochondrial outer membrane. Initially identified through its interaction with the pro-apoptotic protein BID, MTCH2 plays a multifaceted role in mitochondrial biology, including regulating mitochondrial metabolism, apoptosis, and cellular energy homeostasis. Structurally, it belongs to the solute carrier superfamily but lacks canonical transport motifs, suggesting divergent functions. Studies link MTCH2 to lipid metabolism, mitochondrial dynamics (fusion/fission), and the modulation of apoptosis by acting as a receptor for truncated BID (tBID), which facilitates mitochondrial outer membrane permeabilization (MOMP) during cell death signaling.
Recombinant MTCH2 protein is engineered using heterologous expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional protein for experimental studies. This recombinant form retains key structural and functional properties, enabling researchers to dissect MTCH2’s interactions, biochemical activity, and role in diseases. For instance, MTCH2 has been implicated in metabolic disorders (e.g., obesity, diabetes) due to its influence on adipocyte differentiation and insulin sensitivity. Additionally, its involvement in cancer progression, via apoptosis regulation, highlights its therapeutic potential.
The availability of recombinant MTCH2 has advanced *in vitro* and *in vivo* studies, including structural analysis, binding assays, and drug screening. Ongoing research aims to clarify its precise mechanisms in mitochondrial processes and explore its utility as a biomarker or therapeutic target for metabolic and degenerative diseases.
×
